Publications by authors named "Ernesto Marcos Lopez"

The non-human primate (NHP) model (specifically rhesus and cynomolgus macaques) has facilitated our understanding of the pathogenic mechanisms of yellow fever (YF) disease and allowed the evaluation of the safety and efficacy of YF-17D vaccines. However, the accuracy of this model in mimicking vaccine-induced immunity in humans remains to be fully determined. We used a systems biology approach to compare hematological, biochemical, transcriptomic, and innate and antibody-mediated immune responses in cynomolgus macaques and human participants following YF-17D vaccination.

View Article and Find Full Text PDF

Given the time and resources invested in clinical trials, innovative prediction methods are needed to decrease late-stage failure in vaccine development. We identify combinations of early innate responses that predict neutralizing antibody (nAb) responses induced in HIV-Env SOSIP immunized cynomolgus macaques using various routes of vaccine injection and adjuvants. We analyze blood myeloid cells before and 24 h after each immunization by mass cytometry using a three-step clustering, and we discriminate unique vaccine signatures based on HLA-DR, CD39, CD86, CD11b, CD45, CD64, CD14, CD32, CD11c, CD123, CD4, CD16, and CADM1 surface expression.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates how innate immunity affects the adaptive immune response, particularly regarding T- and B-cell memory formation, influenced by vaccine delivery methods.
  • Research on non-human primates revealed differences in immune responses between subcutaneous and intradermal vaccine injections, particularly in innate cell activation and cytokine profiles.
  • Findings suggest that not only is the vaccine's effectiveness influenced by its administration route, but this method also affects the long-term changes in myeloid cells related to innate immune training.
View Article and Find Full Text PDF
Article Synopsis
  • Vaccines are a significant advancement in modern medicine, but ongoing research is needed to develop new vaccines for both existing diseases like tuberculosis and malaria, as well as emerging threats like Zika virus and SARS-CoV-2.
  • Achieving sterilizing immunity through vaccination is the goal, but evaluating how effective vaccines are remains difficult, highlighting the need for better understanding of the immune responses involved.
  • A systems biology approach utilizing advanced technologies and computational models is being employed to improve vaccine research, focusing on identifying immune markers and developing predictive models for vaccine efficacy in both animal and human studies.
View Article and Find Full Text PDF

Viral vectors are increasingly used as delivery means to induce a specific immunity in humans and animals. However, they also impact the immune system, and it depends on the given context whether this is beneficial or not. The attenuated vaccinia virus strain modified vaccinia virus Ankara (MVA) has been used as a viral vector in clinical studies intended to treat and prevent cancer and infectious diseases.

View Article and Find Full Text PDF

Rheumatoid arthritis (RA) is the most common autoimmune rheumatic disease and leads to persistent chronic inflammation. The pathophysiology of the disease is complex, involving both adaptive and innate immunity. Among innate immune cells, neutrophils have been rarely studied due to their sensitivity to freezing and they are not being collected after Ficoll purification.

View Article and Find Full Text PDF

HIV infection is associated with chronic inflammation in both non-treated and treated patients. TLR-dependent mechanisms are strongly involved in the maintenance of this inflammation. Indeed, the residual replication of HIV, the potential viral co-infections, or the products issued from microbial translocation provide TLR ligands, which contribute to trigger innate immune responses.

View Article and Find Full Text PDF

One of the major problems faced for the development of a vaccine against Dengue virus is the lack of a suitable animal model. Although non-human primates do not show overt signs of disease, these animals develop viremia after the infection and are the best model to evaluate vaccine candidates against this pathogen. However, for that purpose, the screening of all animals is mandatory to discard those with previous natural immunity.

View Article and Find Full Text PDF

Our group has developed a subunit vaccine candidate against Dengue virus (DENV) based on two different viral regions, the domain III of the envelope protein and the capsid protein. The chimeric proteins for each serotype (DIIIC1-4), aggregated with the oligodeoxynucleotide 39 M, form the tetravalent formulation named Tetra DIIIC. Tetra DIIIC induces a protective immune response in mice when it is inoculated by intraperitoneal route.

View Article and Find Full Text PDF

A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessiona2tfqtch8159p39s3fbmp03h3n535v2l): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once